Combination of Ibrutinib and As2O3 in the Treatment of CLL

Sponsor
Peking University People's Hospital
Study ID
NCT02757040
Phase
PHASE3
Status
Unknown

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia

Key Dates

Start date
Dec 31, 2016
Status verified
Apr 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2018

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ibrutinib combined with As2O3
    Ibrutinib combined with As2O3
  • Active Comparator: Ibrutinib
    Ibrutinib only

Primary Outcome Measure

overall response rate [ Time Frame: 2 years ]

Central Contacts

Related Studies